Lipoxygenase inhibitors induce death receptor 5/TRAIL-R2 expression and sensitize malignant tumor cells to TRAIL-induced apoptosis

Cancer Science

Volumn 98, Issue 9, 2007, Pages 1417-1423

  Yoshida, Tatsushi ^a   Shiraishi, Takumi ^a,b   Horinaka, Mano ^a   Nakata, Susumu ^a   Yasuda, Takashi ^a,b   Goda, Ahmed E ^a,c   Wakada, Miki ^a   Mizutani, Yoichi ^b   Miki, Tsuneharu ^b   Nishikawa, Akiyoshi ^d   Sakai, Toshiyuki ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^c Tanta University   (Egypt)

^d NATIONAL INSTITUTE OF HEALTH SCIENCES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CELL PROTEIN; DEATH RECEPTOR 5; DOCEBENONE; LIPOXYGENASE INHIBITOR; MESSENGER RNA; NORDIHYDROGUAIARETIC ACID; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN CIAP 1; SMALL INTERFERING RNA; SURVIVIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER THERAPY; COLORECTAL CANCER; CONTROLLED STUDY; DOWN REGULATION; DRUG POTENTIATION; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; UPREGULATION;

APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BENZOQUINONES; CELL LINE, TUMOR; DOWN-REGULATION; DRUG SYNERGISM; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; JURKAT CELLS; LEUKEMIA, T-CELL; LIPOXYGENASE INHIBITORS; MUTANT CHIMERIC PROTEINS; NORDIHYDROGUAIARETIC ACID; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; TNF-RELATED APOPTOSIS-INDUCING LIGAND; UP-REGULATION;

EID: 34547786651     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2007.00559.x     Document Type: Article

References (36)

1. Brash AR. Lipoxygenases: Occurrence, functions, catalysis, and acquisition of substrate. J Biol Chem 1999; 274: 23 679-82.
2. Nie D, Nemeth J, Qiao Y et al. Increased metastatic potential in human prostate carcinoma cells by overexpression of arachidonate 12-lipoxygenase. Clin Exp Metastasis 2003; 20: 657-63.
3. Shappell SB, Olson SJ, Hannah SE et al. Elevated expression of 12/ 15-lipoxygenase and cyclooxygenase-2 in a transgenic mouse model of prostate carcinoma. Cancer Res 2003; 63: 2256-67.
4. Chen X, Wang S, Wu N et al. Overexpression of 5-lipoxygenase in rat and human esophageal adenocarcinoma and inhibitory effects of zileuton and celecoxib on carcinogenesis. Clin Cancer Res 2004; 10: 6703-9.
5. Matsuyama M, Yoshimura R, Mitsuhashi M et al. Expression of lipoxygenase in human prostate cancer and growth reduction by its inhibitors. Int J Oncol 2004; 24: 821-7.
6. Hoque A, Lippman SM, Wu TT et al. Increased 5-lipoxygenase expression and induction of apoptosis by its inhibitors in esophageal cancer: A potential target for prevention. Carcinogenesis 2005; 26: 785-91.
7. Hennig R, Grippo P, Ding XZ et al. 5-Lipoxygenase, a marker for early pancreatic intraepithelial neoplastic lesions. Cancer Res 2005; 65: 6011-16.
8. Hagmann W. Lipoxygenase in human tumor cells. Pathol Oncol Res 1997; 3: 83-8.
9. Timar J, Raso E, Dome B et al. Expression, subcellular localization and putative function of platelet-type 12-lipoxygenase in human prostate cancer cell lines of different metastatic potential. Int J Cancer 2000; 87: 37-43.
10. Shureiqi I, Lippman SM. Lipoxygenase modulation to reverse carcinogenesis. Cancer Res 2001; 61: 6307-12.
11. Wang ZY, Agarwal R, Zhou ZC, Bickers DR, Mukhtar H. Antimutagenic and antitumorigenic activities of nordihydroguaiaretic acid. Mutat Res 1991; 261: 153-62.
12. YuA, Hashimura T, Nishio Y, Kanamaru H, Fukuzawa S, Yoshida O. Anti-promoting effect of nordihydroguaiaretic acid on N-butyl-N-(4-hydroxybutyl) nitrosamine and sodium saccharin-induced rat urinary bladder carcinogenesis. Jpn J Cancer Res 1992; 83: 944-8.
13. Avis IM, Jett M, Boyle T et al. Growth control of lung cancer by interruption of 5-lipoxygenase-mediated growth factor signaling. J Clin Invest 1996; 97: 806-13.
14. Moody TW, Leyton J, Martinez A, Hong S, Malkinson A, Mulshine JL. Lipoxygenase inhibitors prevent lung carcinogenesis and inhibit non-small cell lung cancer growth. Exp Lung Res 1998; 24: 617-28.
15. Ansar S, Iqbal M, Athar M. Nordihydroguairetic acid is a potent inhibitor of ferric-nitrilotriacetate-mediated hepatic and renal toxicity, and renal tumour promotion, in mice. Carcinogenesis 1999; 20: 599-606.
16. Seufferlein T, Seckl MJ, Schwarz E et al. Mechanisms of nordihydroguaiaretic acid-induced growth inhibition and apoptosis in human cancer cells. Br J Cancer 2002; 86: 1188-96.
17. Tong WG, Ding XZ, Witt RC, Adrian TE. Lipoxygenase inhibitors attenuate growth of human pancreatic cancer xenografts and induce apoptosis through the mitochondrial pathway. Mol Cancer Ther 2002; 1: 929-35.
18. Ding XZ, Kuszynski CA, El-Metwally TH, Adrian TE. Lipoxygenase inhibition induced apoptosis, morphological changes, and carbonic anhydrase expression in human pancreatic cancer cells. Biochem Biophys Res Commun 1999; 266: 392-9.
19. Walczak H, Miller RE, Ariail K et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 1999; 5: 157-63.
20. Ashkenazi A, Pai RC, Fong S et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999; 104: 155-62.
21. Lawrence D, Shahrokh Z, Marsters S et al. Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat Med 2001; 7: 383-5.
22. MacFarlane M, Ahmad M, Srinivasula SM, Fernandes-Alnemri T, Cohen GM, Alnemri ES. Identification and molecular cloning of two novel receptors for the cytotoxic ligand TRAIL. J Biol Chem 1997; 272: 25 417-20.
23. Pan G, Ni J, Wei Y-F, Yu G-L, Gentz R, Dixit VM. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 1997; 277: 815-18.
24. Sheridan JP, Marsters SA, Pitti RM et al. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 1997; 277: 818-21.
25. Walczak H, Degli-Esposti MA, Johnson RS et al. TRAIL-R2: A novel apoptosis-mediating receptor for TRAIL. EMBO J 1997; 16: 5386-97.
26. Wu GS, Burns TF, McDonald ER 3rd et al. KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nat Genet 1997; 17: 141-3.
27. LeBlanc HN, Ashkenazi A. Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ 2003; 10: 66-75.
28. Takimoto R, El-Deiry WS. Wild-type p53 transactivates the KILLER/DR5 gene through an intronic sequence-specific DNA-binding site. Oncogene 2000; 19: 1735-43.
29. Wu GS, Burns TF, McDonald ER 3rd et al. Induction of the TRAIL receptor KILLER/DR5 in p53-dependent apoptosis but not growth arrest. Oncogene 1999; 18: 6411-18.
30. Wang S, El-Deiry WS. Requirement of p53 targets in chemosensitization of colonic carcinoma to death ligand therapy. Proc Natl Acad Sci USA 2003; 100: 15 095-100.
31. Zhang L, Fang B. Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther 2005; 12: 228-37.
32. Nakata S, Yoshida T, Horinaka M, Shiraishi T, Wakada M, Sakai T. Histone deacetylase inhibitors up-regulate death receptor 5/TRAIL-R2, and sensitize apoptosis induced by TRAIL/APO2-L in human malignant tumor cells. Oncogene 2004; 23: 6261-71.
33. Horinaka M, Yoshida T, Shiraishi T et al. Luteolin induces apoptosis via death receptor 5 upregulation in human malignant tumor cells. Oncogene 2005; 24: 7180-9.
34. Ghosh J, Myers CE. Arachidonic acid stimulates prostate cancer cell growth: Critical role of 5-lipoxygenase. Biochem Biophys Res Commun 1997; 235: 418-23.
35. Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis. Cancer Res 1994; 54: 4855-78.
36. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997; 88: 323-31.